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Abstract HIV research has identified approaches that can
be combined to be more effective in transmission reduction
than any 1 modality alone: delayed adolescent sexual debut,
mutual monogamy or sexual partner reduction, correct and
consistent condom use, pre-exposure prophylaxis with oral
antiretroviral drugs or vaginal microbicides, voluntary med-
ical male circumcision, antiretroviral therapy (ART) for
prevention (including prevention of mother to child HIV
transmission [PMTCT]), treatment of sexually transmitted
infections, use of clean needles for all injections, blood
screening prior to donation, a future HIV prime/boost vac-
cine, and the female condom. The extent to which evidence-
based modalities can be combined to prevent substantial
HIV transmission is largely unknown, but combination
approaches that are truly implementable in field conditions
are likely to be far more effective than single interventions
alone. Analogous to PMTCT, “treatment as prevention” for
adult-to-adult transmission reduction includes expanded
HIV testing, linkage to care, antiretroviral coverage, reten-
tion in care, adherence to therapy, and management of key
co-morbidities such as depression and substance use. With
successful viral suppression, persons with HIV are far less
infectious to others, as we see in the fields of sexually
transmitted infection control and mycobacterial disease con-
trol (tuberculosis and leprosy). Combination approaches are
complex, may involve high program costs, and require
substantial global commitments. We present a rationale for
such investments and cite an ongoing research agenda that
seeks to determine how feasible and cost-effective a combi-
nation prevention approach would be in a variety of epi-
demic contexts, notably that in a sub-Saharan Africa.
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Introduction
Many infectious diseases have required a combination of
approaches to reduce transmission [1]. Tuberculosis control
relies on case detection, treatment, and contact tracing to
find yet more cases for prophylaxis or treatment (Table 1).
Malaria control may incorporate bed nets, vector control,
intermittent presumptive treatment, case finding and treat-
ment, and we hope in the not-too-distant future, a malaria
vaccine. Nosocomial infections may use rigorous multi-
component protocols to ensure the full array of preventive
strategies in health care settings. Helminth infections may be
controlled with combinations of sanitation, vector control,
mass chemotherapy, and surveillance to assess where the
major impact may be seen (Table 1). HIV is a sexually
transmitted infection (STI), propagated by human sexual
behavior. Other STIs have required combinations of case
finding and treatment, behavior change (eg, fewer sexual
partners), risk reduction (eg, condoms), and even structural
changes (eg, 100 % condom use policies in brothels) to
achieve successful control. The inability to cure HIV with
current therapies renders its effective control much more
challenging.
A feature of many STIs is the replenishment of an at-risk
pool of persons as children age into adolescence and
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adulthood. About half of the world’s global population is
under age 25 and it is estimated that nearly half of all HIV
infections are also among persons under age 25, most ages
15-24 [2]. The intensity of risk for adolescents and youth is
especially high in sub-Saharan Africa once they become
sexually active, given the likelihood of a sexual partner
being HIV-infected [3–7]. Over a third of infected persons
globally live in just 10 nations of southern Africa where the
epidemic is driven by heterosexual contact [8, 9]. Injection
drug use and male-to-male sexual contact seem to be in-
creasing in this region, and are the major drivers of the
epidemic in other parts of the world [10–31]. Iatrogenic
spread is also prevalent [32, 33].
While individual approaches to HIV prevention have had
some success, most interventions are of limited, partial, or
unproven effectiveness. Any single intervention is unlikely
to be sufficient to achieve the steep reductions in incidence
that is needed to bring the epidemic under control, especial-
ly in sub-Saharan Africa where high rates of transmission in
the general population are the norm.
Elements of Combination Prevention
Evidence for efficacy of elements of combination preven-
tion can come from observational data (as with male con-
doms or reduction in partner numbers) or from randomized
clinical trials (RCTs; as with male circumcision or early
treatment as prevention). What elements might be consid-
ered essential for successful combination prevention are a
matter of debate, but can be elucidated with decision-
analysis and HIV transmission models (Table 2). A consen-
sus is emerging that combination prevention should be
anchored on the use of combination antiretroviral therapy
(cART) given that infected persons who receive and are
adherent to cART regimens can suppress HIV replication
and reduce their infectiousness [34, 35, 36•, 37]. As of this
writing (late 2012), Ministries of Heath of low and middle
income countries (LMIC) typically limit their start of cART
at the World Health Organization (WHO) recommended
threshold of CD4+ cell counts <350/μL or WHO clinical
status 3 or 4 [37]. Some of the most resource-limited nations
continue to authorize the start of cART at a lower threshold
like <250 cells/μL, despite overwhelming evidence that this
is too late for optimal clinical response [38]. A large pro-
portion of transmissions occur before patients reach the
usual thresholds for ART initiation, however, a rationale
for treating at earlier CD4+ cell counts (or even universal
ART for all HIV-infected persons).
The HIV Prevention Trials Network 052 protocol (HPTN
052) was an RCT that assessed early initiation of cART at
CD4+ cell counts of up to 550/μL, demonstrating both
reduced transmission of HIV to sexual partners as well as
clinical benefits to their infected partners on cART [40••].
Table 1 Examples of infectious
diseases for which combination
prevention approaches are es-
sential for reducing transmis-
sion: Tuberculosis, Malaria,
Nosocomial infections, Hel-
minths [325–328]
Infection and key
strategy
Key elements for control strategies using tools available in 2013 (note that many
elements listed under 1 disease might well apply to other diseases)
Tuberculosis: Directly
Observed Treatment,
Short Course
• Political commitment and adequate financing
• Case detection with high quality diagnostics, including drug sensitivities
• Standardized treatment with patient support to maximize adherence
• Effective drug supply and management system
• Monitoring and evaluation to measure impact
Malaria: Reducing the
basic reproduction rate
• Reduction of human infectivity with early diagnosis and effective treatment
• Reduction in vectorial capacity with effective, sustained mosquito control
• Avoidance of mosquito bites through consistent use of bed-nets
• Intermittent presumptive treatment
• Measures to reduce global warming
• Partially protective vaccine
Nosocomial infections:
Reducing patient
exposures
• Enhanced real-time surveillance and immediate feedback
• Implementation of clinical protocols based on evidence-based interventions, eg,
○ Hand hygiene, vaccines, clean environment, prudent prescribing
• Training, audit, and performance management focus
(targets, legislation)
○ Management commitment to rigorous protocols, eg, flu vaccine
Helminths: Control of
poly-worm infections
• Vector control, eg, specific species of snails, mosquitoes, black flies
• Reduce exposures, eg, laundries away from streams, dispose fecal waste
• Case finding and treatment; mass drug administrations
• Disease surveillance with concentrated effort on highest intensity infections
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Hence it is disappointing that only 19 %–28 % (range of
estimates) of Americans infected with HIV were on cART
with successful suppression of HIV viral load [40••, 41••,
42•, 43•]. Even if these are overly pessimistic estimates due
to some “lost-to-follow-up” patients possibly being in ther-
apy elsewhere, the true rates of ART coverage and viral
suppression are disappointing, in both high and low income
nations [44–47, 48•, 49•, 50–53, 54•, 55•]. In selected
venues, ecological evidence of prevention benefits from
cART is emerging [56•, 57••, 58]. Ecological analyses in
San Francisco, Vancouver, China, Taiwan, and KwaZulu-
Natal have suggested that higher cART coverage may
Table 2 Elements of combination prevention likely to synergize to improve the effectiveness of prevention programs for HIV infection [184•,
329•, 330, 331•, 332–335]
Goal(s) to be achieved
Personal elements
Treatment as prevention Increased HIV testing, linkage to care, coverage with cART, retention and adherence; lower viral
load and infectiousness
Voluntary medical male circumcision In high prevalence areas driven by heterosexual transmission dynamics, increase circumcision
among men
Abstinence Encourage delayed sexual debut among adolescents
Partner reduction Encourage mutual monogamy and reduced sexual partners
Physical barriers Market male condoms widely, and where appropriate, female condoms
Chemical barriers Pre-exposure prophylaxis with antiretroviral drugs, both oral and topical (ie, microbicides)
STI control Reduce both ulcerative and non-ulcerative STIs via diagnosis, treatment, and partner notification
(contact tracing)
Prevention of mother to child transmission Universal testing of pregnant women and protocol-driven ART for mother and newborn child
Nosocomial and iatrogenic transmission Clean needle use for all medical encounters; use of infection-screened blood products with modern
blood-banking techniques
Societal elements
School attendance Maximal school attendance by children and youth
Workplace policies Enable workers to live with their families
Human rights and legal protections Protect the rights of HIV-infected persons, widows, minority populations such as men who have
sex with men, women/girls, vulnerable populations
Structural changes 100 % condom policies in brothels and universal availability in public places, hotels, and key
venues where high risk sex occurs
Community mobilization Engage communities in HIV control; reduce stigma, increase disclosure of status, increase coverage and
adherence
Program elements
Health workforce development Increase substantially the numbers of health care providers for both rural and urban settings;
Efficient allocation of tasks
Integration of services Nest HIV/AIDS care and treatment within sustainable primary care and reproductive care services,
including family planning
Physical infrastructures Provide basic electricity, water, medical waste disposal, and space for health centers
Pharmacy logistics systems Ensure that inventory management, shipping, and storage systems avoid supply (eg, test kits) and
drug stock-outs
Laboratory development Decentralize laboratory work, as much as possible and affordable, with point-of-care diagnostic tests
Quality of care and iterative evaluation Build sustainable quality improvement research and systems improvement efforts into HIV care
programs
Hub-and-spoke models of care Bring primary and HIV/AIDS care closer to people who are remote from major clinical services;
home-based HIV testing
Data management systems Build sustainable, affordable electronic medical record systems to harmonize the myriad of systems
now extant
Community engagement to support
programs
Implement innovative community models of outreach, retention, and adherence support, including
patient-to-patient and family-to-patient
Cultural changes in the health sector Train staff and reform procedures to protect patient confidentiality/privacy, provide more respectful,
client-friendly services in familiar local languages
Management and administration Train and capacitate health systems to use modern business practices for financial and logistical
management
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correlate with lower seroincidence rates [56–61]. However, it
is unknown whether these correlations represent success of
TasP or whether other factors are contributing [62, 63].
Vancouver is a case in point. Investigators and public health
officials have addressed prevention of HIV with needle/syringe
exchange and opiate substitution therapy among Vancouver
IDUs at the same time that cART was being made available
[64]. Hence, it is hard to disaggregate the prevention impact of
needle/syringe exchange and expanded heroin addiction thera-
py from cART expansion or other factors. Western Europe is
also a region of interest [65]. It is easy to speculate that easy
access to HIV testing and widespread cARTuse within national
health systems may have resulted in lowering HIV incidence
rates in Western Europe, but it is hard to know whether other
sociocultural factors or prevention efforts also made impacts.
However, in the United Kingdom where access to testing and
treatment is facilitated by the National Health System (NHS)
with free services available to all, no reduction in the incidence
of new infections in MSM has been noted to date, so interpret-
ing European experiences is not always clear-cut.
The option of moving to immediate offering of ART—
irrespective of CD4+ cell count-is being supported by public
health policy in San Francisco, Vancouver, New York City,
and elsewhere. If HIV testing were expanded markedly and
all persons were treated shortly after diagnosis and successful
virally suppressed, then fewer infectious persons would be
transmitting to others and the epidemic might decline. Wheth-
er this is possible is the topic of intense current investigation.
Suboptimal cART Coverage and Viral Suppression
Patient management issues are complex for HIV disease (Ta-
ble 2). Rather than the lethal diagnosis for so many in the pre-
treatment era, HIV disease is now a chronic, manageable
disease. It requires HIV testing, linkage to care, cART avail-
ability, national guidelines permitting cART administration,
and adherence to lifelong therapeutic regimens. In the US,
current systems fail to meet the full need of HIV-infected
patients, many of whom have co-morbidities that inhibit full
viral suppression [41••, 42•, 43•]. These may include sub-
stance use (eg, drugs and/or alcohol), mental health problems,
financial and health care insurance challenges, transportation
issues, and stigma/disclosure challenges [66–87]. In LMICs, it
is plausible that less than 10 % of all infected persons are
successfully virally suppressed. Stigmatized persons who do
not “come out” may not reach medical care or be retained in
care, as is the case with Black men who have sex with men
(MSM) in the US [88–99]. Adolescents with HIV infection
have demonstrated abysmal adherence rates in some studies
[100–108]. Children with HIVare dependent on their parents
or guardians; many children have not had their HIV status
disclosed to them andmay not be participating actively in their
ongoing care [109–115].
The gulf between current guidelines for high income
countries where all HIV-infected persons are typically of-
fered cART vs WHO and LMIC Ministries of Health guide-
lines that offer a smaller proportion of HIV-infected persons
cART (typically persons under 350 CD4+ cells/μL) is worth
highlighting. By definition, the latter policies have a larger
pool of infected persons who remain virally unsuppressed. If
resources were obtained to treat all HIV-infected individuals
(ie, universal, immediate cART), the proportion of infec-
tious persons would decline. If a large enough pool of
infectious persons were made non-infectious, mathematical
models suggest a decline in new infections. It is not certain
that a test-and-treat prevention strategy is feasible, accept-
able, sustainable, and affordable. The most resource-limited
LMICs depend on the programmatic resources available
from the President’s Emergency Program for AIDS Relief
(PEPFAR) and the Global Fund to Fight AIDS, Tuberculo-
sis and Malaria; local Ministries of Health rarely have the
resources to find, link, and retain HIV-infected persons in
cART-based care, with optimized adherence [116–120]. The
long-term management of chronic diseases in LMICs is
challenging; HIV investments may serve as a backbone for
also addressing a wide variety of diseases requiring chronic
management [39, 47, 52, 121–131, 132•, 133–138].
We also do not knowwhether a test-and-treat approach will
have the postulated benefits in a real world circumstance.
Whether we can further enhance its benefits with other pre-
vention modalities without overwhelming the public health
and clinical systems is also unknown. While behavior change
is a component of all approaches, some combined interven-
tions only make sense in certain epidemic circumstances, as
with male circumcision in generalized epidemics and needle
exchange where IDU drives transmissions.
Adapting for Local Epidemics
HIV is a disease based on patterns of human behavior;
hence, it is affected and modulated by stigma, discrimina-
tion, prejudice, fear, stress, depression, denial, and igno-
rance [80, 139]. Many have compared AIDS to the leprosy
of the Bible when infected persons were shunned and even
banished. Since HIV is transmitted similarly to patterns for
other sexual and blood-borne agents, it is subjected to the
same societal distress surrounding other STIs. HIV trans-
mission is more likely in the face of multiple sexual partners
(ie, high mixing rates) and failure to use condoms, so
persons acquiring infection are typically judged by others
[8]. However, we must put stigma into its modern perspec-
tive. While a major problem in most areas, especially per-
haps in concentrated epidemics in marginalized risk-groups,
there are also signs of “normalization” of HIV as a public
health problem in both higher income and LMICs, including
in southern Africa. We speculate that wider access to cART
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has contributed to an improving social environment for
many persons living with HIV.
Much progress has been made in the avoidance of iatro-
genic and occupational parenteral transmission unclean sy-
ringes and needles through single use technologies,
serological screening of blood or blood products, and poli-
cies to reduce inadvertent needle sticks in an occupational
health care setting. Progress, too, has been made in offering
universal screening of pregnant women and the offering,
uptake, and adherence to 1 of a variety of antiretroviral
therapy options, pre-partum, intra-partum, or post-partum,
to avoid mother-to-child transmission that can take place in
utero, during delivery, or from breastfeeding, respectively
[140–144]. Yet too often, successful programs are not inte-
grated and potential synergies for combination prevention
are lost. If testing/treatment successes in PMTCT, say, could
be expanded into the analogous treatment as prevention
cascade for adults, we might well combine components of
prevention into an integrated whole, with the kind of impact
on incidence not often seen in the global pandemic.
Hepatitis B virus (HBV) is spread in ways reminiscent of
HIV, though HBV is typically more communicable [145,
146]. Our tools for HBV control include active and passive
immunization, tools that are not yet available for HIV con-
trol. In addition, HIV infection is not yet curable, such that
persons whose viral loads are not suppressed can transmit
the infection for many years. Other STIs can also be spread
via blood-borne routes (eg, syphilis, hepatitis C virus
[HCV], and human T-lymphotropic virus type 1 [HTLV-
1]), but sexual routes are the dominant mode of transmission
for most STIs, as with HIV. The CD4+ T-lymphocyte tro-
pism of HIV makes it unique among the STIs and its
penchant for deep lymphoid tissue invasion and quiescence
are the roots of it incurability.
Stigma, Discrimination, Poverty, and Human Rights
HIV spread is steeped in gender inequality, poverty, dis-
crimination based on sexual preference and identity, and
perverse public policies that exacerbate the epidemic, rather
than control it. One’s perspective on the role of stigma in
fueling the epidemic must recognize both the fear that an
HIV diagnosis still engenders among many, and the fact that
increased HIV testing and adherence to cART-based care
represent signs of “normalization” of HIV as a public health
challenge in many countries, including some in southern
Africa, where wider access to cART has probably contrib-
uted to HIV being seen to be more like other diseases.
Russia’s failure to legalize and promulgate clear needle
distribution and opiate substitution therapy, the continued
demonization of MSM in many African countries, and the
insistence on ineffective “abstinence only” educational
investments in the US are all examples of policy gone awry
[4, 26, 147–155]. In the face of the politicization of
HIV/AIDS, policymakers failing to use existing tools to
prevent HIV transmission are responsible for much prevent-
able infection [156]. Failure to protect the blood supply
early in the epidemic led to the infection of tens of
thousands of blood and blood product recipients worldwide,
especially persons with hemophilia. The taboo of politi-
cians, religious leaders, teachers, or even health care pro-
viders discussing sexual risk reduction frankly and clearly
keeps issues of HIV prevention from being fully integrated
into political, religious, and social discussions. This is unfor-
tunate since some themes— delaying adolescent coital debut
and reducing numbers of sexual partners, for example — are
widely supported goals in nearly all circles and political
philosophies. While condoms are opposed by some due to a
conviction that they may lead to higher risk sexual activities
and/or that they may violate certain religious proscriptions
against contraception, there is no strong evidence for the
former view and support for the latter may be waning. For
example, a major global religious leader who previously op-
posed condom use stated in a 2010 book that "there may be a
basis in the case of some individuals, as perhaps when a male
prostitute uses a condom, where this can be a first step in the
direction of a moralization, a first assumption of responsibil-
ity." [157]. The religious leader later indicted that he also was
referring to female prostitutes when he suggested that condom
use may actually be a morally superior choice to prevent
transmission to others. Such changes in attitude can be influ-
ential in empowering at-risk persons to protect themselves
without going counter to religious views to which they may
subscribe.
Failures in public policy have consequences. Modelers
have quantified public policy failures, particularly the fail-
ure to provide clean needles and syringes for IDUs in the US
from 1987–1995, estimating that an excess of between 4394
and 9666 infections, representing a third of incident IDU
cases, was the result [158]. The attendant excess costs to the
US were US$244 to $538 million. It will be a major stride in
the HIV field if public health advocacy for evidence-based
prevention could be the basis for HIV control policy and
investment [26].
Behavior Change
Even in the face of biomedical interventions such as TasP or
voluntary medical male circumcision, behavior change is an
essential component of prevention interventions; for exam-
ple, persons must agree to and adhere to the given interven-
tion. All by itself, however, behavior change to reduce HIV
incidence has not proven robust [159]. In studies designed
to enhance adherence to ART, for example, the impact of
behavioral interventions has often be very contextual or
transient [160]. The HIVNET 015 Project EXPLORE
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protocol in MSM in the US sought to lower HIV incidence
with an intensive 10-visit educational program that included
reinforcement sessions [161–163]. Investigators were disap-
pointed with the 18.2 % reduction (95 % CI: -4.7 %, 36.0 %)
in HIV incidence in the intervention group compared with a
control group receiving a short intervention [163]. However,
given that the benefits were even lower in substance users
and persons with mental health problems, this underscored
the importance of attending to these co-morbidities in order
to reduce HIV transmission [164–166].
For TasP, willingness to test for HIV, be linked to care, and
adherence to cART to reduce infectiousness all require be-
havioral support. Pre-exposure prophylaxis (PrEP) using
cART in seronegative persons to prevent infection, and in-
creased testing and linkage to cART require high levels of
adherence to be successful. “Serosorting” is when HIV se-
ropositive persons have sex only with other infected persons,
and HIV-seronegatives seek other uninfected persons for
sex; this obviously requires a great deal of self-efficacy and
motivation. Substance abuse treatment, including needle
exchange, alcohol treatment, and opiate substitution therapy,
as needed, depend on motivated and able clients. Contingen-
cy cash transfers are rewards for lowering risk behaviors, and
depend on behavior change and political support.
Classic “ABC” approaches ofAbstinence/Be faithful/Con-
dom advocacy are fully dependent upon behavioral change
[42•, 167–176]. The US Centers for Disease Control and
Prevention (CDC) has published its evidence-based interven-
tions for risk reduction in the US; they are heavily
behaviorally-based [177–181]. Abstinence-only education
has been unsuccessful in reducing risk and was paradoxically
associated with higher pregnancy rates than more comprehen-
sive educational approaches that included STI prevention
advocacy based on abstinence, partner reduction, and condom
use [150, 153, 182]. It is the consensus in the HIV scientific
community that “ABC” principles are vital guides for public
health intervention, but are better bundled with biomedical
prevention approaches; lone behavioral change approaches
are not likely to stop the global pandemic [42•, 89, 183, 184•].
Linked to behavior change, but worthy of separate consid-
eration are the so-called “structural interventions”. This
involves changing laws, policies, or other societal norms to
reduce risk behavior. Raising cigarette taxes to reduce tobacco
use among youth or banning cigarette smoking in indoor
spaces where the public has access are examples of structural
interventions. If schools were improved, school fees eliminat-
ed as obstacles to full attendance, and after-school opportuni-
ties for youth were promulgated, this might be considered a
structural change to seek to reduce substance abuse in higher
income nations and the exchange of sexual services for money
to attend school as happens in many LMICs. A law requiring
all commercial transient lodgings (hotels, etc.) to provide in-
room condoms would be another example of a structural
intervention. Large scale programs to offer universal testing
in saturation volumes, incentives to link persons with HIV to
care, near-universal use of cART for all HIV-infected persons,
and community partnerships to maximize clinic attendance
and cART adherence are the backbone of TasP programs that,
while still depending on behavioral adherence, would be
enhanced considerably if a structural context could be pro-
mulgated by policymakers of routine, widespread, opt-out
testing.
Packages of Tools for Combination Prevention
“Magic bullets” have not worked to control the epidemic on
their own, with the possible exceptions of needle exchange for
IDUs and blood screening for blood banks. Even if we had a
proven, effective vaccine for HIV, vaccination would still re-
quire multiple voluntary visits to optimize immunization along
with large-scale population mobilization and program expan-
sion for children, adolescents, and/or adults, depending on
vaccine characteristics (durability of protection, for example).
Combination prevention packages must vary to target those at-
risk persons who are at highest risk in a given epidemiologic
context [185]. If the local epidemic is being driven by IDU, then
needle exchange and addiction treatment will be the best strat-
egies, along with primary prevention of drug abuse. If sex work
is a principal driver of a local epidemic, community and polit-
ical mobilization of sex workers and their employers (eg,
brothel owners, pimps, madams) will be needed to ensure
effective STI screening and treatment, to promote universal
condom use, and perhaps to provide PrEP. Other efforts to offer
sex workers a way out of the profession through protection and
job retraining and job placement, as well as to control sexual
trafficking, can help protect the womenwho are aided, and may
or may not reduce prostitution or HIV incidence overall.
Some interventions have far stronger levels of evidence of
efficacy to reduce HIV transmission (infectiousness) or acqui-
sition (susceptibility) than others. Among these are voluntary
medical male circumcision (VMMC) with compelling obser-
vational data supported by 3 definitive and remarkably con-
sistent RCTs [186–189]. ART for prevention was begun as a
concept with the definitive demonstration of prevention of
maternal-to-child transmission (PMTCT) with ART dating
from 1994 [190]. Observational data from 2000–2001 and
an incidental finding in a clinical trial in 2010 suggested that
cART would reduce sexual transmission [191, 192, 193•].
Finally, the HPTN 052 RCT, over a decade in the making,
demonstrated early use of cART as a major tool to reduce
infectiousness and sexual transmission to partners, while clin-
ically benefiting the infected persons as well [40••].
Other strategies are logical as adjunctive tools for HIV
prevention, but are less consistently beneficial in RCTs. STI
control based on syndromic management worked very well in
one Tanzanian epidemic context to reduce HIV transmission,
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but has failed in other epidemic contexts and other treatment
[194]. PrEP has had a mixed success: Tenofovir-containing
PrEP (cART among HIV-seronegative at-risk persons) was
successful in CAPRISA 004 (topical microbicide for women),
iPrEx (MSM) and Partners PrEP, and TDF-2 studies (hetero-
sexual men and women), but not in the large VOICE trial
(heterosexual women), or the FemPrEP studies (heterosexual
women) [195•, 196•, 197, 198]. The Thai vaccine prime-boost
strategy published in 2009 was partially effective; however,
the vaccine companies did not seek licensure for market-
ing of either the prime or boost products, given their
very modest effects [199•, 200]. Nonetheless, as better
oral and vaginal PrEP/microbicide and vaccine products
are developed, they may be added as future components
to the therapeutic armamentarium. Given that PrEP is a
tool for use in seronegative persons and TasP a tool for
use in seropositive persons, work is needed to assess
how these might be combined to maximize potential
HIV impact at the community level.
When RCT data are not available, observational data are
used to make judgments as to likely efficacy. Evidence of
male condom efficacy is confirmed by effectiveness studies
[184•]. Evidence for efficacy and effectiveness of female
condoms is inconsistent, but they have been reported helpful
in selected contexts [201–204]. Of certain utility, but not
backed up by RCT evidence are needle exchange for drug
users and opioid substitution therapy for IDUs [64,
205–223]. Also convincing are the use of contraception
for HIV-infected women to reduce unintended pregnan-
cies and HIV infection in infants [224–253]. A variety
of behavioral and structural interventions that reduce
HIV-related risk behaviors are of possible, but uncertain
utility, due to conflicting trial and study evidence [175,
254–267].
Testing and Linkage to Care as a Core Strategy
The person who knows his or her own HIV serostatus is in a
position to access HIV prevention or care services as they are
provided in a given community; thus, testing is a first gateway
[266–288]. While persons testing HIV seronegative may not
change their risky behaviors, persons testing HIV seropositive
tend to reduce their sexual transmission risk behaviors signif-
icantly [289–291]. Persons who do not know their own or
their partners’ serostatus are far less likely (range of 50 %–
66%) to use condoms [292, 293]. It is estimated that <20% of
adults in sub-Saharan Africa have been tested for HIV, yet the
HPTN 043 NIMH Project ACCESS study demonstrated in a
community RCT how community mobilization can increase
testing rates up to 10-fold [294, 295]. The best HIV testing
access includes provider-initiated, routine or opt-out testing,
and voluntary home-based HIV counseling and testing
(HBCT) [194, 290]. HBCT may be cost-effective for
population-level scale-up in generalized epidemics, despite
its higher programmatic costs [296].
Once a person is tested for HIV, those testing positive must
be linked to cART-based care. In the HPTN 052 trial, excel-
lence in cART care and adherence reduced viral replication
and reduced HIV transmission to sexual partners by 96 %,
termed a “game-changer” by the director of UNAIDS [40••].
HIV-infected persons with 350–550 CD4+ cells/μL were
assigned randomly to receive ART either immediately (early
therapy) or after a decline in the CD4 count to 250–350 cells/
μL or the onset of HIV-1-related symptoms (delayed therapy).
Given the success of TasP in HPTN 052 when persons with
high CD4+ cell counts were the target, the option of immedi-
ate treatment for all HIV-diagnosed persons, regardless of
immunological status is ideal, if resources are available.
Still, a combination of interventions is inherently needed
to make TasP a reality in public health terms: HIV testing
has to be brought to scale, effective linkage to care must be
a key priority for primary care programs, and high cover-
age and adherence to cART must be nurtured. WHO’s
estimate of a 23 % yearly ART attrition rate in Africa
illustrates the tremendous challenge faced by the public
health community in this regard [297]. It is plausible that
a universal testing and treatment approach (regardless of
CD4+ cell count) could reduce stigma in communities
where testing is common and infection is simply treated
in everyone, as with other infectious diseases or chronic
disease conditions.
Given this need for expanded HIV testing, accessing the
service, and willingness to adhere to the prevention modality
(eg, VMMC, future HIV vaccine or microbicide, cART regi-
men, consistent and correct condom use), behavioral co-
interventions are essential. Prevention for positives to reduce
risky behaviors with counseling focused on building motiva-
tion and developing skills is promising [298]. Interventions
based on sound behavioral theory, such as the Health Belief
model, can help address mental health and substance use
issues, with a focus on adherence [67]. Condom use will
continue to be emphasized as an adjunctive tool for HIV/STI
risk reduction [292, 299, 300]. The biomathematics of
combining methods for prevention are compelling, but
intimidating at the same time; substantial coverage will
be needed to succeed in bringing the basic reproductive
rate to <1 thereby offering the potential prospect of
eventual elimination of HIV as a public health problem
[34, 301–309, 310•, 311–313].
The PopART Intervention
Led by one of us (RJH), our protocol team is launching a trial,
HPTN 071/PopART, designed to measure the impact on HIV
incidence of an intervention package that combines TasP,
VMMC, STI control, PMTCT, and key behavioral approaches
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Table 3 Key elements of the combination prevention community ran-
domized clinical trial, HPTN 071: population effects of antiretroviral
therapy to reduce HIV transmission (PopART): a cluster-randomized trial
of the impact of a combination prevention package on population-level
HIV incidence in Zambia and South Africa (to begin in 2013), Concep-
tual reference [331•]
Study Purpose and Design: To determine the impact of two community-level combination prevention packages on population-level HIV incidence. Both
interventions are based on universal HIV testing and intensified provision of combination antiretroviral therapy (cART) and care, one with cART for all
HIV infected persons and one only for persons meeting national treatment guidelines (CD4+ cells e350/μL and/or WHO clinical groups 3 or 4. PopART is
a three-arm, cluster-randomized, longitudinal study to be implemented in 21 clusters (communities).
Study Population and Size: The prevention packages will be implemented throughout the communities randomized to the intervention arms. Main study
outcomes will be measured in a randomly-selected group drawn from the adult population of the communities: a Population Cohort. The combined
population of all 21 clusters is approximately 1.2 million individuals. The interventions will be implemented in 14 of the 21 clusters with a combined
population of approximately 800,000 individuals (adults and children) in the intervention arms. The approximate sizes of the randomly-selected groups for
main study outcome assessments are:
• Population Cohort: 52,500 individuals
• Case–control Studies: 2400 individuals
• Qualitative Studies: ≈2000 individuals
Study Sites: The study communities in Zambia are spread across 4 provinces and 5 districts. Each community is the catchment population of a government
health facility. The study communities in South Africa are located in the Cape Metro District and Cape Winelands District of the Western Cape Province.
The communities are defined by the catchment population of a government health facility. For a list of all sites, see: http://www.hptn.org/research_studies/
hptn071.asp.
Study Duration: The planned duration of the entire study will be approximately 6 years, with enrollment and follow-up of communities and delivery of the
intervention occurring over 4 years.
Intervention Packages:
Arm A - Universal testing with immediate cART.
•House-to-house deployment of:
•Universal HIV counseling and testing;
•Active linkage to care for persons diagnosed as HIV-infected, with immediate cART eligibility
•Promotion of male circumcision and prevention of mother to child transmission (PMTCT); and
•Provision of condoms.
•Strengthening of HIV testing and services at health facilities and other venues.
•Strengthening of male circumcision and prevention of mother-to-child transmission of HIV services available in the community.
•Treatment of sexually transmitted infections (STIs) and provision of condoms at health units.
Arm B - Universal Testing with cART Eligibility According to National Guidelines Package includes all of the Arm A interventions, except cART
eligibility according to national guidelines.
Arm C - Standard of Care (Control Arm).
•Strengthening of HIV testing and cART services according to national guidelines at health facilities and other venues.
•Strengthening of male circumcision and PMTCT available at health facilities and other venues in the community.
•Treatment of STIs and provision of condoms at health facilities and other venues in the community.
Primary Objectives: To measure the impact of the 2 intervention packages on HIV incidence by enrolling and following a random sample of adults
(Population Cohort) in the trial communities.
Secondary Objectives:
•Measure the impact of the 2 intervention packages on the following:
•HIV incidence over the first, second, and third years of follow-up;
•Community viral load, cART drug resistance, and cART adherence and viral suppression (if funding is identified);
•HSV-2 incidence; Sexual risk behavior; HIV-related stigma;
•Uptake of HIV testing and retesting over the entire study period;
•cART screening and uptake; cART toxicity based on clinic records;
•Time between HIV diagnosis and initiation of care; Uptake of PMTCT;
•Retention in care; HIV disease progression and death;
•Case notification rate of tuberculosis;
•Uptake of male circumcision.
• Carry out case–control studies to examine factors related to:
•Uptake of HIV testing during the first round of home-based testing in Arms A and B;
•Uptake of immediate treatment in Arm A;
•Uptake of HIV testing during the second round of home-based testing in Arms A and B.
•Use qualitative methods to:
•Assess popular understanding of testing/treatment at study initiation and during implementation;
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to reduce infection at the community level (Table 3). There are
other small and large clinical and community research efforts
to access the impact of various TasP and combination preven-
tion approaches [36•, 313–318].
Conclusions
There is substantial heterogeneity in the global HIVepidemic,
with the drivers of the epidemic differing substantially bymode
of transmission (eg, heterosexual, homosexual, IDU) [319].
Regardless of the mode of transmission, the HIV pandemic
can be confronted with a combination of approaches, anchored
by the deployment of cART that can reduce infectiousness as
well as the clinical boon of turning a previously fatal disease
into a chronic, manageable one. Complementary preventive
approaches must differ. For example, needle/syringe exchange
is important for IDU-related prevention, voluntary medical
male circumcision addresses heterosexual transmission in high
prevalence areas like sub-Saharan Africa, and PrEP has poten-
tial to help prevent male-to-male transmission. The promise of
combination prevention depends on the long-term resolution of
huge health services gaps in LMICs. Yet as we have more tools
for HIV prevention, “HIV-fatigue” in donor nations combined
with concern from economic downturns from 2008 onwards
may result in cuts in HIV programs. Past experience suggests,
however, that failures in HIV prevention or early treatment
will simply cost society more in the long run, given the
high direct costs of illness and indirect costs of disability,
suffering, and death [320–324]. Prevention, including testing
and early cART treatment, is a good societal and economic
investment.
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